Research Article
Multi-site data from Klarity clinics demonstrates how PHQ-9, HRV, and sleep architecture respond to titrated ketamine sessions paired with integrative psychiatry.
Executive Summary
Klarity’s observational cohort of 212 patients demonstrates a 62% median reduction in PHQ-9 scores after four ketamine-assisted psychotherapy sessions. Heart rate variability (HRV) and wearable sleep architecture captured via Oura sensors show dose-responsive improvements that mapped tightly to integration adherence.
Key takeaways
- Measurement-based care enables rapid protocol adjustments.
- Integration participation predicts HRV normalization.
- Real-time dashboards prevent plateauing antidepressant responses.
Methodology
- Population: Adults aged 24–68 with treatment-resistant depression (TRD) treated at three Klarity clinics between Q1–Q3 2024.
- Protocol: Six intravenous ketamine sessions (0.5–1.0 mg/kg) partnered with integrative psychiatry and somatic coaching.
- Measurement cadence: PHQ-9 and GAD-7 captured pre/post every session; nightly HRV and sleep recorded via wearables; PROMIS Emotional Support delivered weekly.
Outcomes
-
PHQ-9 trajectory
- 38% of participants achieved remission (<5) by session 4.
- 14% required a booster series; boosters correlated with low integration attendance.
-
HRV stabilization
- Baseline RMSSD: 21 ms → Session 6 RMSSD: 36 ms.
- Cohorts receiving guided breathwork during integration accelerated HRV gains by 19%.
-
Sleep architecture
- REM latency normalized after session 3 for 61% of participants.
- Deep sleep duration increased by 32 minutes on average.
Clinical Implications
- Rapid feedback loops allow psychiatrists to titrate or extend dosing when PHQ-9 reductions plateau.
- Integration quality holds equal weight to pharmacological dosing; sessions with documented breathwork and journaling correlated with durable outcomes.
- Wearable data bridges hospitality rituals and clinical oversight, giving nurses tangible signals when to adjust IV nutrient support.
Suggested Keywords
- ketamine therapy outcomes
- neuroplasticity biomarkers
- treatment-resistant depression data
- Klarity Clinic research
References
- Dore, J., et al. “Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression.” The Permanente Journal, 2021.
- Alessi, S., et al. “Wearable Biomarkers in Psychedelic-Assisted Therapy.” Frontiers in Psychiatry, 2023.
- Klarity Clinic Internal Registry (2024 Q1–Q3 data extract).